Mir-19, the drug for the treatment of coronavirus, is indicated for use in people aged 18 to 65 years, TASS reports referring to the instructions for the drug.
“Indication for use: treatment of the novel coronavirus infection (COVID-19) in adults aged 18 to 65 years,” the instructions say.
The medicine is administered by inhalation twice a day for 14 days.
“The drug is administered with a mesh inhaler (nebulizer). The drug is prescribed for use in hospital settings. The drug is to be administered twice a day. Seven to six hours have to pass between inhalations. … The drug is administered for 14 days (28 inhalations),” the instructions say. It is noted that nasal congestion, if any, should be eliminated before inhalation by rinsing with saline solution or administering a vasoconstrictor drug.
Mir-19 must not be used in pregnant or breastfeeding women, as well as in cases of severe coronavirus infection. It may be also used, with caution, in patients with autoimmune diseases and malignant neoplasms.
The drug was developed by the Federal Medical-Biological Agency (FMBA) and is intended for the prevention or treatment of coronavirus infection through inhalation or intranasal administration. According to the FMBA, it stops the replication of the virus and prevents the most severe forms of coronavirus infection, as well as concommitant pneumonia and acute respiratory distress syndromes.
On December 22, the Ministry of Health of the Russian Federation registered Mir-19.
